Cullinan Therapeutics, Inc.
CGEMNasdaq
$17.69
↑ +7.8%Jul 17 close · end-of-day
Price
1Y↑ +130.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
-1329.0%
Debt / Equity
—
Net Cash
$351.9M
Return 1Y
+127.7%
Company profile
Cullinan Oncology Inc. focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- CEO
- Nadim Ahmed
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Massachusetts
- Website
- cullinanoncology.com
Management & directors
- Michaelson JenniferChief Scientific Officer
- Fenton Mary KayChief Financial Officer
- Sumer Jacquelyn LChief Legal Officer
- Ahmed NadimPresident and CEO
- Jones Jeffrey AlanChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
CGEM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $18.9M | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$60.3M | -$68.0M | $144.6M | -$191.1M | -$196.9M | -$241.6M |
| Net income | -$51.8M | -$65.6M | $111.2M | -$155.1M | -$167.6M | -$219.9M |
| Diluted EPS | — | -$1.52 | $2.38 | -$3.69 | — | — |
| Operating cash flow | -$29.8M | -$43.4M | -$126.7M | -$134.3M | -$145.3M | -$175.8M |
| Free cash flow | -$29.8M | -$43.4M | -$127.8M | -$134.5M | -$145.3M | -$175.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -358.7% | — | — | — | — |
| Net margin | — | -346.1% | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$50.0M | -$48.9M | -$55.0M | -$55.0M | -$75.8M | -$55.6M | -$55.3M | -$53.7M |
| Net income | -$42.0M | -$40.6M | -$47.8M | -$48.5M | -$70.1M | -$50.6M | -$50.7M | — |
| Diluted EPS | -$0.75 | -$0.69 | — | — | — | — | — | — |
| Operating cash flow | -$36.3M | -$34.1M | -$36.6M | -$43.2M | -$57.6M | -$36.9M | -$38.1M | -$46.0M |
| Free cash flow | -$36.3M | -$34.1M | -$36.6M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Michaelson Jennifer· Chief Scientific Officer | Sale | 8,000 | $17.82 | $142,560.00 | filing |
| 2026-07-06 | Michaelson Jennifer· Chief Scientific Officer | Option exercise | 4,000 | $4.30 | $17,200.00 | filing |
| 2026-06-30 | SUMER JACQUELYN L· Chief Legal Officer | Award | 2,470 | $8.60 | $21,242.00 | filing |
| 2026-06-30 | Fenton Mary Kay· Chief Financial Officer | Award | 1,541 | $8.60 | $13,252.60 | filing |
| 2026-05-05 | Michaelson Jennifer· Chief Scientific Officer | Sale | 7,800 | $14.60 | $113,880.00 | filing |
| 2026-05-05 | Michaelson Jennifer· Chief Scientific Officer | Option exercise | 4,000 | $4.30 | $17,200.00 | filing |
| 2026-05-05 | Michaelson Jennifer· Chief Scientific Officer | Sale | 200 | $15.58 | $3,116.00 | filing |
| 2026-03-05 | Michaelson Jennifer· Chief Scientific Officer | Sale | 8,000 | $15.68 | $125,440.00 | filing |
| 2026-03-05 | Michaelson Jennifer· Chief Scientific Officer | Option exercise | 4,000 | $4.30 | $17,200.00 | filing |
| 2026-02-25 | Michaelson Jennifer· Chief Scientific Officer | Sale | 1,780 | $14.14 | $25,169.20 | filing |
| 2026-02-24 | AHMED NADIM· President and CEO | Sale | 13,515 | $14.47 | $195,562.05 | filing |
| 2026-02-24 | Jones Jeffrey Alan· Chief Medical Officer | Sale | 4,582 | $14.47 | $66,301.54 | filing |
| 2026-02-24 | SUMER JACQUELYN L· Chief Legal Officer | Sale | 3,601 | $14.47 | $52,106.47 | filing |
| 2026-02-24 | Michaelson Jennifer· Chief Scientific Officer | Sale | 3,601 | $14.47 | $52,106.47 | filing |
| 2026-02-23 | Michaelson Jennifer· Chief Scientific Officer | Sale | 1,752 | $13.99 | $24,510.48 | filing |
| 2026-02-20 | AHMED NADIM· President and CEO | Sale | 16,381 | $13.62 | $223,109.22 | filing |
| 2026-02-20 | Michaelson Jennifer· Chief Scientific Officer | Sale | 8,000 | $14.30 | $114,400.00 | filing |
| 2026-02-20 | Jones Jeffrey Alan· Chief Medical Officer | Sale | 4,982 | $13.62 | $67,854.84 | filing |
| 2026-02-20 | Fenton Mary Kay· Chief Financial Officer | Sale | 4,398 | $13.62 | $59,900.76 | filing |
| 2026-02-20 | Michaelson Jennifer· Chief Scientific Officer | Sale | 3,742 | $13.62 | $50,966.04 | filing |
| 2026-02-20 | SUMER JACQUELYN L· Chief Legal Officer | Sale | 3,742 | $13.62 | $50,966.04 | filing |
| 2026-02-20 | Michaelson Jennifer· Chief Scientific Officer | Option exercise | 8,000 | $4.30 | $34,400.00 | filing |
| 2026-02-18 | Fenton Mary Kay· Chief Financial Officer | Award | 68,750 | $0.00 | $0.00 | filing |
| 2026-02-18 | Michaelson Jennifer· Chief Scientific Officer | Award | 57,500 | $0.00 | $0.00 | filing |
| 2026-02-12 | Michaelson Jennifer· Chief Scientific Officer | Sale | 416 | $12.03 | $5,004.48 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.